Entities

Draig Therapeutics director and head of Access Biotechnology, with life sciences investment experience.

Draig Therapeutics director representing Canaan Partners, listed in the company's current public directory.

Draig Therapeutics director, whose current company directory identifies an outside affiliation with Q32 Bio.

Draig Therapeutics board observer representing Sanofi Ventures, listed in its current public directory.

Draig Therapeutics board observer representing ICG, listed in its current public directory.

Clinical-stage biotechnology company developing investigational medicines for neuropsychiatric disorders through selective modulation of AMPA and GABA receptors. Its lead AMPA receptor potentiator, DT-101, is in Phase 2 studies for major depressive disorder. Co-founded in 2024 by Cardiff University and SV Health Investors, with operations in Cardiff and Massachusetts.

Draig Therapeutics scientific advisory board member, identified as head of early R&D at ViiV Healthcare in its current directory.

Has been an Alto director since February 2024. His current Alto biography identifies him as co-chair of the UK Mental Health Mission and a University of Oxford professor, with prior neuroscience leadership at Johnson & Johnson and Janssen. He also serves on Draig Therapeutics’ scientific advisory board.

Draig Therapeutics scientific advisory board member, identified as an adjunct psychiatry professor at Yale University in its current directory.

Draig Therapeutics scientific advisory board member and University of Toronto professor of psychiatry and pharmacology, as identified in its current directory.

Axent Biosciences is a preclinical biotechnology company developing stem-cell therapies using engineered biomaterials. Its AXgel platform uses fully synthetic, biocompatible materials to manufacture stem cells at scale and provide protective environments for cell implantation. Its lead indication is Parkinson’s disease. The company was founded in 2019 from research in David Schaffer’s laboratory at UC Berkeley.

XGEN Venture is a Milan-based venture capital fund manager that builds and invests in early-stage life-sciences companies developing therapeutics, medical devices and diagnostics. Its portfolio includes gene therapies for refractory epilepsy and rare diseases, oncology treatments and cardiovascular technologies. Established by the former Genextra team in 2021, it invests through the XGEN Venture Life Science Fund and separately advises Genextra on its legacy portfolio.

Schrödinger president and head of therapeutics R&D and chief strategy officer for partnerships. Joined in 2018 and leads drug development, strategic ventures and business development.

Schrödinger executive vice president and chief scientific officer for its platform, leading computational scientists and chemists. Earned his chemistry doctorate at Columbia University with Richard Friesner.

Schrödinger senior vice president of software development, with scientific software and computational chemistry expertise. Joined in 2003 following research training at MIT and Columbia University.

Schrödinger executive vice president and chief information officer, with high performance computing and information technology experience. Joined the company in 2009.

Schrödinger executive vice president and chief commercial officer, leading global software sales and marketing. Has extensive computational chemistry and software commercialization experience, including earlier Schrödinger sales leadership from 2017 to 2024.

Schrödinger senior vice president of discovery and preclinical development sciences. Joined in 2016 and has medicinal chemistry, discovery portfolio and preclinical development expertise.

Schrödinger senior vice president of software sales. Joined in 2014 and has led commercial activities in the Americas and Asia Pacific, following roles at ChemAxon and Accelrys.

Schrödinger senior vice president of materials science. Joined in 2012 and has computational materials modeling experience at Materials Design, Accelrys and Zyvex.

Schrödinger chief financial officer, joining in 2024 after serving as a managing director in Morgan Stanley's healthcare investment banking group. Previously worked as an electrical engineer at Boston Scientific.

Schrödinger senior vice president of biology and structural biology. Joined in 2017 and leads biological discovery and structural biology capabilities supporting drug development.

Schrödinger senior vice president of life science business. Joined in 2008 and has experience developing European life science software markets, partnerships and scientific customer relationships.

Schrödinger executive vice president, chief technology officer and chief operating officer for software. Joined in 2006 and has led development of scientific software including Maestro and LiveDesign.

Schrödinger chief corporate affairs officer and head of investor relations. Joined in 2020 after communications and investor relations roles at Gamida Cell and Sanofi.

Schrödinger senior vice president of life sciences products. Joined in 2002 and has computational chemistry and molecular docking expertise, including development of Glide.

Schrödinger chief legal officer and chief people officer. Joined in 2010 following intellectual property and commercial legal work at Oracle and DoubleClick.

Schrödinger senior vice president of scientific development. Joined in 2012 and specializes in physics-based drug discovery and free energy methods, with doctoral research at Columbia University.

Schrödinger president, chief executive and director. Joined the company in 2002, became CEO in 2017 and led its 2020 IPO; previously a chemistry professor at Rutgers University.

Computational chemistry company combining physics-based molecular simulation and artificial intelligence to support drug discovery and materials design. Develops scientific software, collaborates with pharmaceutical and biotechnology partners and advances its own investigational therapeutic programs. Founded in 1990; publicly traded on Nasdaq as SDGR.

Schrödinger director with enterprise software sales and operating leadership experience. Previously led global sales at Red Hat and served as chief executive of Viridity Software.

Schrödinger scientific adviser and Columbia University researcher specializing in biophysics, structural bioinformatics and macromolecular electrostatics, including DelPhi and GRASP methods.

Schrödinger scientific adviser and UCSF pharmaceutical chemistry professor specializing in molecular docking, chemoinformatics and experimental drug discovery.

Schrödinger director and Motive Partners senior partner. Previously held senior executive roles during an eighteen-year career at IBM.

Schrödinger director with biotechnology finance leadership experience. Previously served as chief financial officer at Nabriva Therapeutics and Synergy Pharmaceuticals.

Schrödinger director and physician with clinical drug development experience, including service as Vertex Pharmaceuticals' chief medical officer and advisory work with Blackstone Life Sciences.

Schrödinger director and drug discovery executive. Serves as Kallyope's R&D chair following service as its founding chief executive; previously spent three decades in research at Merck.

Schrödinger scientific adviser and University of Maryland researcher specializing in computational chemistry and machine learning, including therapeutic discovery at the Institute for Health Computing.

Schrödinger co-founder, director and scientific advisory chairman. Founded the company in 1990 and is a Columbia University chemistry professor specializing in computational chemistry and molecular modeling.

Schrödinger scientific adviser and Caltech professor with computational chemistry and materials simulation expertise, leading the Materials and Process Simulation Center.

Kerna Ventures is an early-stage venture capital firm investing in advanced therapeutic platform technologies, from seed through Series B. Its focus includes genome engineering, cell reprogramming, computational biology and drug delivery. Its neuroscience investments include RNA delivery across the blood-brain barrier, cell therapies for Parkinson’s disease and gene therapy for focal refractory epilepsy. The firm was founded in 2022.

Saras Capital is a London-based early-stage investment firm backing companies at the intersection of technology and biology. It invests in AI and software for the biopharmaceutical industry, computational therapeutics and AI-native biotechnology companies. Its second fund, Saras Capital II LP, reached a final close in January 2026. The firm is legally Saras Capital LLP and operates as an appointed representative of Midmar Capital LLP.

Bernard Ravina is listed by Atlas Venture as atlas advisor. The same directory identifies an outside portfolio role: Founder and Chief Executive Officer, Vima Therapeutics. The affiliation belongs to Atlas’s biotechnology company-creation network. Company operating roles, advisory posts and prior appointments are distinguished from full-time fund-management employment; the profile does not establish a personal cash investment.

Professor of Neurology at UCL and a consultant neurologist at the National Hospital for Neurology and Neurosurgery; scientific founder and advisor of Focalis Bio. Distinct from the S2G Investments managing director of the same name.

Technology entrepreneur and individual biotechnology investor. Nimbus Therapeutics' financing announcements explicitly name Bill Gates as an investor; those personal investments are distinct from Gates Frontier, Gates Ventures and the Gates Foundation. Gates Foundation public biography: As chair of the Gates Foundation, Bill Gates shapes and approves foundation strategies, advocates for the foundation’s issues, and sets the organization’s overall direction. He works with grantees and partners to further the foundation’s goal of improving equity in the United States and around the world. Bill co-founded Microsoft Corporation in 1975 with Paul Allen and led the company to become the worldwide leader in business and personal software and services. In 2008, Bill transitioned to focus full-time on the foundation’s work. Through his private office, Gates Ventures, he pursues his work in climate change and clean energy innovation, Alzheimer’s research and other healthcare issues, interdisciplinary education, and technology. He is also the founder of Breakthrough Energy, which works to address climate change by supporting the next generation of entrepreneurs, big thinkers, and clean technologies. If we are going to change people’s lives, we need another level of innovation. Not just technology innovation – system innovation. - Bill Gates Chair and Board Member Bill Gates established Gates Ventures as his private executive office in September 2008. The office supports his work through research, innovation, partnerships and investment activities. This institutional affiliation is separate from his personal investor identity and the Gates Foundation.

Founder of Nimbus, an electric vehicle startup in Ann Arbor that joined Y Combinator's Winter 2020 batch. YC currently lists Nimbus as inactive and identifies him as a former founder.

Nimbus Therapeutics chief financial officer with finance and biotechnology experience; previously CFO at Boston Pharmaceuticals and Catabasis Pharmaceuticals and a pharmaceuticals analyst at Cowen.

Nimbus Therapeutics president of research and development, overseeing discovery, nonclinical and clinical groups; joined as chief scientific officer in 2019 and has extensive drug discovery experience.

Nimbus Therapeutics senior vice president of chemistry with oncology medicinal chemistry experience; previously led Boston oncology chemistry at AstraZeneca and held drug discovery roles at Merck.

Nimbus Therapeutics senior vice president of clinical development and physician scientist with oncology clinical strategy and small molecule and immuno-oncology development experience.

Nimbus Therapeutics senior vice president of biology with precision oncology, cancer immunology and metabolic drug discovery experience; previously held research leadership roles at HotSpot Therapeutics, FogPharma and Agios.

Nimbus Therapeutics vice president of molecular sciences, with biochemistry, biophysics and structural biology expertise; previously worked at Delphia Therapeutics, MOMA Therapeutics and Novartis.

Nimbus Therapeutics vice president of program management and R&D strategic operations; previously led therapeutic programs at the Gates Medical Research Institute and Mersana Therapeutics.

Nimbus Therapeutics vice president of corporate affairs and communications with biotechnology communications, medical affairs and strategic operations experience at Shape Therapeutics, Wave Life Sciences, Sanofi and Biogen.

Nimbus Therapeutics vice president of chemistry, manufacturing and controls; previously led CMC at Achillion Pharmaceuticals, developing clinical candidates and their manufacturing processes.

Nimbus Therapeutics vice president of medicinal chemistry, with experience in kinase, GPCR and lipase drug discovery; joined Nimbus in 2017 after a long career at Pfizer and Wyeth.

Nimbus Therapeutics vice president of computational chemistry and structural biology; previously a computational chemistry director at GSK with structure-based drug discovery, informatics and ADME modeling experience.

Nimbus Therapeutics vice president of intellectual property, also known as Josh Roth; pharmaceutical patent attorney and chemist with experience at Bristol Myers Squibb, Novartis and Pfizer.

Nimbus Therapeutics vice president of information technology with biotechnology digital infrastructure and cybersecurity experience; previously held technology leadership roles at Orchard Therapeutics and AMAG Pharmaceuticals.

Clinical-stage biotechnology company using computational chemistry, structure-based design and machine learning to discover and develop investigational small molecule medicines. Its programs target cancer, immunological and metabolic diseases. Founded as Nimbus Discovery in 2009 and renamed Nimbus Therapeutics in 2015; headquartered in Boston.

Nimbus Therapeutics chief executive and director; previously chief business officer, with biotechnology financing, licensing and asset transaction experience at the company since 2014.

Nimbus Therapeutics director with healthcare finance and strategic advisory experience, including Havencrest Healthcare Partners and leadership of Grant Thornton's healthcare and life sciences practices.

Nimbus Therapeutics chairman and co-founder, with biotechnology venture investment and company building experience at Atlas Venture.

Nimbus Therapeutics director and drug discovery executive with research and operating leadership experience at Navitor Pharmaceuticals and Sirtris.

Nimbus Therapeutics director with biopharmaceutical and medical device investment experience at Lightstone Ventures and Advanced Technology Ventures.

Nimbus Therapeutics director and physician with clinical research, medical affairs and patient safety leadership experience; previously held research leadership roles at Agilent and Kaleido.

Nimbus Therapeutics director and biotechnology investor with neuroscience research training; has investment experience at RA Capital Management spanning cell therapies, retinal disorders and neurodevelopmental diseases. Current source-verified RA affiliation: Laura Stoppel holds the source-published role of Partner within RA Capital Management’s Healthcare group. The individual directory reports joining in2016; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: Harvard University, Massachusetts Institute of Technology. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Nimbus Therapeutics director with pharmaceutical development and commercialization leadership experience at Inhibikase, Kala, Civitas, Blend and Sunovion.

Nimbus Therapeutics vice president of drug metabolism, pharmacokinetics and clinical pharmacology, joining in 2024; previously led nonclinical disposition and bioanalysis at Bristol Myers Squibb and worked at Celgene, Amgen and Abbott.

Global Health Investment Corporation (GHIC) is a nonprofit investment manager that uses public, philanthropic and private capital to develop and commercialize technologies addressing global health challenges. It invests in vaccines, therapeutics, diagnostics and other medical technologies, with a focus on health security and access in underserved populations. Its Global Health Security Fund partners with BARDA to support medical countermeasures and enabling technologies.

Physician appointed Akili senior vice president and head of medical affairs November13,2018. Prior medical-affairs and clinical-development work included Pfizer psychiatry, Sanofi, PPD and Shire. This dated appointment does not establish current employment.

Bertelsmann Investments is Bertelsmann’s venture capital and growth investment division. It backs technology businesses through investment platforms including BAI, Bertelsmann India Investments and futurepresent, and develops businesses in areas including mobile advertising, human resources technology and digital health through Bertelsmann Next. It co-led deepc’s July 2024 financing. Its constituent funds and operating companies are distinct from the parent investment division.

deepc builds software infrastructure for hospitals to deploy and operate clinical artificial intelligence. Its vendor-neutral deepcOS platform connects radiology AI applications with medical imaging systems, supports their integration into clinical workflows, and provides tools to manage and monitor deployments. The Munich company was founded in 2019.

Meridian Health Ventures is an early-stage venture capital firm investing in health technology, clinical software and digital health. Founded in 2021 as KHP Ventures, it works with NHS partners to help startups validate and adopt products and supports expansion between the UK and US. It manages the Meridian Health Ventures I transatlantic fund and the Innovations in Mental Health fund, which focuses on technologies addressing depression, anxiety and psychosis.

SwissHealth Ventures is the corporate venture investment company of Swiss health insurer CSS. Established in 2020, it invests in digital health startups that improve access to care, prevention, diagnosis, treatment and coordination of healthcare. Its portfolio includes radiology AI infrastructure company deepc and brain stimulation company Flow Neuroscience. The CHF 100 million allocated by CSS is a corporate investment budget, rather than a newly closed fund.

Winning Mindset Ventures is a Munich-based private investment company that holds equity stakes in businesses. Its disclosed investments include deepc, which develops clinical AI infrastructure for hospitals. It participated in deepc’s July 2024 Series A extension. The company’s legal imprint identifies Stephan Huber as managing director.

Pooja Sikka is a CBIV Venture Partner and practising medical doctor with more than 20 years in healthcare and life sciences. She was a Partner at Octopus Ventures and previously led EY UK’s healthcare corporate venture portfolio. She founded and exited a healthcare service business and has worked on digital health and healthcare adoption strategy. She holds an Imperial College MBA and medical qualifications.

Managing director of Winning Mindset Ventures GmbH in Munich; identified in the company’s imprint as Dipl.-Betriebswirt Stephan Huber. Distinct from XISTA’s physician-scientist venture partner of the same name.

Tim Irish is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His health-technology experience includes GSK, GE and Philips. He has taught at King’sCollegeLondon, served as NICE vice-chair and held external board appointments. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

SV Health Investors growth fund advisory board member and biopharmaceutical strategy adviser with experience in institutional investing and research and development valuation; co-founder of Mezzopointe.

SV Health Investors growth fund advisory board member and healthcare executive with hospital network leadership experience at McLaren Health Care.

SV Health Investors growth fund advisory board member with healthcare technology leadership experience at athenahealth, AMICAS and VitalWorks, and investment advisory experience at New Mountain Capital.

SV Health Investors growth fund advisory board member with pharmaceutical services executive and legal experience; previously led Leiters, Ricerca Biosciences and GeneraMedix.

SV Health Investors growth fund advisory board member and founder of Aerocare; formerly chief executive of AdaptHealth, with durable medical equipment and healthcare services experience.

SV Health Investors growth fund advisory board member and hospital system executive with healthcare operations and leadership experience at Methodist Le Bonheur Healthcare.

SV Health Investors growth fund advisory board member with healthcare services and technology operating experience, including Nordic Consulting Partners, Vitalize Consulting Solutions and Cross Country.

SV Health Investors business support and office coordinator in London, joining in 2026; previously worked in executive support, audit and business management at HSBC and Société Générale.

SV Health Investors growth fund advisory board member and healthcare entrepreneur; founder of Hightop Health and Maestro Health, with previous executive experience at Wondr Health and PayFlex.

SV Health Investors executive assistant supporting its biotechnology team, joining in 2025; previously supported executives at Glia Technologies, Ethos Capital and Three Bays Capital.

SV Health Investors finance director with fund finance and accounting experience at Evans Capital and several private investment firms; previously SV's controller.

SV Health Investors healthcare growth executive assistant with executive support and operations experience at Odyssey Therapeutics and American Renal Associates.

SV Health Investors executive assistant supporting Kate Bingham and the London biotechnology team; previously worked at Credit Suisse.

SV Health Investors executive assistant supporting its biotechnology team, joining in 2024; previously held executive support and human resources roles at Crosspoint Capital Partners and RA Capital Management.

SV Health Investors partner, chief financial officer and chief compliance officer; previously controller at CMGI @Ventures and a senior associate at PricewaterhouseCoopers.

SV Health Investors controller with finance and accounting experience at Bain Capital and PricewaterhouseCoopers.

SV Health Investors financial controller in London, joining in 2025; previously handled corporate and fund accounting at OpCapita.

SV Health Investors venture partner and drug discovery executive with immunometabolism company building experience at Sitryx; formerly led discovery research at UCB and Celltech.

SV Health Investors venture partner and physician scientist with biopharmaceutical research and clinical development leadership experience at Sitryx, Sobi, Aeglea, GSK and Roche Genentech. Ravi Rao is listed by Samsara BioCapital as Venture Partner. He joined Samsara’s venture-partner network in2022. His physician-scientist background spans development, manufacturing and commercialization; this role is preserved alongside independently documented SVHealth affiliation.

SV Health Investors executive in residence focused on healthcare financial risk and services; healthcare company founder with operating experience at Health Payment Systems, Minuteman Health, Averde and UnitedHealth Group.

SV Health Investors venture partner and biotechnology company builder with leadership experience at Enara Bio, Immunocore, Quartet Medicine and Annovation Biopharma.

SV Health Investors venture partner and pharmaceutical research leader with experience at Sitryx, Quench Bio and Pfizer, spanning inflammation, immunology and early clinical development.

SV Health Investors venture partner and antibody discovery scientist with biotechnology leadership experience at Alchemab and MedImmune; former chair of the UK BioIndustry Association.

SV Health Investors operating partner and drug discovery specialist; previously chief scientific officer of OMass Therapeutics and chief technology officer of Sosei-Heptares.

SV Health Investors venture partner and biotechnology executive with company building and business development experience at Mestag Therapeutics, Gyroscope Therapeutics, Orbit Biomedical and Freeline.

Listed as a venture partner on SV Health Investors' current roster; physician and drug development executive with previous chief medical officer roles at Circassia, Theravance Biopharma and ReViral.

SV Health Investors executive in residence focused on healthcare provider models, services and technologies supporting value-based care; has payer and provider operating experience including CIGNA and UnitedHealth Group.

SV Health Investors venture partner and physician scientist with transplantation and immunology experience; joined SV in 2025 after pharmaceutical leadership roles at GSK, Celgene and Janssen.

SV Health Investors operating partner and biotechnology company executive; founder and former chief executive of Rempex Pharmaceuticals and former chief executive of Mpex Pharmaceuticals.

SV Health Investors growth partner investing in healthcare services, medical device and pharmaceutical services, and healthcare information technology; previously a principal at Graham Partners.

SV Health Investors biotechnology senior associate, joining in 2026; previously a KB Investment investor and a drug discovery and biology leader at Roivant Sciences and Merck.

SV Health Investors operating partner and growth fund advisory board member; former chief executive of CAS Medical Systems and QDX, with medical device operating and transaction experience.

SV Health Investors managing partner focused on medical devices and healthcare services, with investment, fundraising and portfolio experience at the firm since 2002.

SV Health Investors managing partner leading medical device investments; formerly chief operating officer of Boston Scientific, with experience integrating acquisitions and developing medical technology businesses.

SV Health Investors operating partner and growth fund advisory board member with medical device leadership experience at Resolution Medical, GI Supply, Hill-Rom and Medtronic.

SV Health Investors healthcare growth senior associate, promoted in 2025; previously invested at Lineage Capital and advised life sciences companies at Putnam Associates.

SV Health Investors chairman, also known as Gene Hill, with healthcare services and information technology investment experience; formerly an Accel Partners partner and healthcare company executive.

SV Health Investors' inaugural AI Fellow, joining its London office in July 2026 to implement AI workflows; previously worked on neurodegenerative drug development at Talisman Therapeutics and stem cell disease models at Pfizer's Neusentis.

SV Health Investors managing partner focused on healthcare services and growth companies; previously a partner at Ferrer Freeman & Co. and held investment roles at GE Capital and Prudential.

SV Health Investors healthcare growth vice president, promoted in 2025 after joining in 2022; previously worked on healthcare and life sciences acquisitions at Thermo Fisher Scientific.

SV Health Investors biotechnology partner and life sciences company builder, joining in 2024 after 5AM Ventures; has operating experience across venture-backed therapeutic companies including Sage and Nido.

SV Health Investors managing partner investing in digital health, healthcare technology and growth-stage services; previously a general partner at Summit Partners and Edison Partners.

Milan-based biotechnology company developing potential treatments for Alzheimer’s disease by targeting microglia, the brain’s resident immune cells. Its discovery program investigates a microglial pathway with the aim of changing the course of neurodegeneration. Scientific founder Marco Colonna’s neuroimmunology research underpins the company, which launched publicly in March 2025 with backing from Sofinnova Biovelocita II and CEO Gabriella Camboni. Specific drug candidates, molecular targets and clinical efficacy have not been publicly established.

University of Edinburgh spin-out developing precision medicines for fibrosis across multiple organs. Forth combines single-cell and spatial genomics with computational models and machine learning to map disease-associated cells, identify antifibrotic targets and develop targeted therapies. Its platform draws on a large human liver-disease dataset and research led by scientific founder Neil Henderson. The company publicly describes three development assets but has not disclosed their specific molecular targets or clinical results. It operates from the Edinburgh and Cambridge research hubs with backing from Sofinnova Partners and Old College Capital.

The University of Edinburgh’s venture investment operation, managed within its commercialisation service Edinburgh Innovations. Old College Capital invests in university-associated deep technology startups and spin-outs from pre-seed through Series A and reinvests returns under an evergreen model. OCC Launch offers early convertible investments of up to GBP100,000, while OCC Ventures typically makes initial investments of GBP150,000–350,000 alongside other investors. The team also manages the university’s founding shareholdings through OCC Equity; these licence-related stakes are distinct from cash investments.

Neuroimmunology researcher and Professor of Pathology and Immunology at Washington University School of Medicine in St. Louis. His research on brain immune cells informs BioClec’s Alzheimer’s drug discovery program.

Academic hepatologist and Chair of Tissue Repair and Regeneration at the University of Edinburgh. He studies the cells and molecular pathways that cause organ fibrosis using single-cell and spatial genomics.

Antibody and biologics discovery specialist with experience developing therapeutic platforms and clinical-stage drugs at Cambridge Antibody Technology, MedImmune, AstraZeneca and Alchemab.

Head of IT at SV Health Investors, managing technology infrastructure in the UK and US and supporting biotechnology and dementia strategies.

London accountant at SV Health Investors supporting biotechnology and dementia strategies, with prior experience preparing management accounts at BE Offices.

Senior associate in investor relations at SV Health Investors, supporting biotechnology and dementia strategies; previously worked in academic communications and fundraising.

UK chief compliance officer at SV Health Investors; previously led compliance at ACA Mirabella and worked at the Financial Conduct Authority.

SV Health Investors operating partner supporting dementia and biotechnology strategies; neuroscientist, former Innovate UK chief executive and biotechnology company builder.

SV Health Investors venture partner associated with Dementia Discovery Fund; former Eli Lilly neurodegenerative disease chief scientific officer with tau and progranulin research experience. Mike Hutton is a TRIMTECH scientific adviser. He led neurodegeneration discovery at Eli Lilly from 2009 until retiring in October 2025, with later responsibilities covering genetic medicine. His earlier research at Mayo Clinic and MSD included genetic causes of frontotemporal dementia. This advisory role does not imply current Lilly employment.

Scientific adviser associated with Dementia Discovery Fund and neurologist researching neuroinflammation; directs the Luxembourg Centre for Systems Biomedicine.

SV Health Investors managing partner co-leading its biotechnology franchise, with investments in drug discovery and development; formerly chair of the UK Vaccine Taskforce.

Novoroo Bioscience project manager coordinating Australian research and collaborations; global health graduate and Tasmania doctoral researcher with prior Novoron laboratory experience.

Medicinal chemist contributing to Novoroo Bioscience; Monash University researcher with industry and academic experience in fragment-based drug discovery.

Novoroo Bioscience structural biologist with protein biochemistry and structural research experience at Cambridge, Sydney and Tasmania.

Novoroo Bioscience structural biologist using cryo-electron microscopy and biophysical methods to investigate LRP1 interactions; trained at Monash University and the University of Melbourne.

Novoroo Bioscience director and MStranslate co-founder; former laboratory researcher in multiple sclerosis at the University of Melbourne and science communication specialist.

Novoroo Bioscience is a Melbourne biotechnology company and wholly owned Australian subsidiary of Novoron Bioscience. Its Australian entity was registered in 2022 as Novoron Australia Pty Ltd and adopted the Novoroo name in April 2023. The company develops investigational therapies targeting low-density lipoprotein receptor biology, including LRP1, to address spinal cord injury, remyelination and neurodegenerative protein propagation. Its work combines structural biology, medicinal chemistry and preclinical research, with staff and collaborators in Melbourne, Hobart and San Diego. Travis Stiles serves as CEO, alongside directors Brett Drummond and Shawn Gahr and a scientific and research coordination team. In January 2026, the Christopher & Dana Reeve Foundation and Spinal Research announced a $250,000 two-year grant to Novoroo for preclinical NOVO-120 studies addressing bladder dysfunction after spinal cord injury. The company also participates in an Australian collaborative research initiative on myelin repair led by the Menzies Institute for Medical Research.

Corporate venture capital arm of Japan’s Taiho Pharmaceutical investing in early-stage biotechnology companies relevant to oncology, allergy, immunology and urology. It backs therapeutic platforms and drug developers through equity investments, company creation, spin-outs and option-based investments. Its current website reports USD400 million under management; this is aggregate managed capital rather than a newly verified fund close.

Héloïse Percheron appears in Idinvest Partners’ August2020 primary directory as HR coordinator. The role belonged to the historical European investment manager’s published investment, investor-relations or corporate support platform, spanning venture/growth, private debt and dedicated portfolios. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

Josh Makower is a senior adviser to Patient Square Capital, a Stanford professor and co-founder of Stanford Biodesign. His work combines medical-device entrepreneurship, investment and clinical innovation; he founded ExploraMed and previously worked with NEA.

Barcelona biotechnology company developing gene-writing tools for advanced cell and gene therapies. Its FiCAT platform combines CRISPR-Cas targeting with an engineered piggyBac transposase to insert small or large genetic payloads with precise, stable genome integration. Founded as a Pompeu Fabra University spin-out by Marc Güell and Avencia Sánchez-Mejías, Integra is developing the platform for preclinical CAR-T therapies and other cell-engineering applications, alongside a gene therapy for a rare paediatric liver disease. Its work includes protein engineering and AI-assisted design; these programs remain in development.

Paris-based preclinical biotechnology company developing off-the-shelf immunotherapies for solid tumours by engineering monocytes directly inside the patient. Its platform builds on Gustave Roussy research into p21 (CDKN1A), a regulator of myeloid immune-cell activity, to reprogram innate immune cells and counter tumour-driven immune suppression. Lead program SiB-2101 is advancing toward candidate nomination. Scientific founders Jean-Luc Perfettini and Nathalie Chaput created the company with Sofinnova Partners and Gustave Roussy; Selwyn Ho is its current CEO. The technology remains preclinical.

Biopharmaceutical company builder and partner in Sofinnova’s Biovelocita strategy. He leads Forth Therapeutics and previously served as founding CEO of Alchemab and CEO of Creabilis.

Antoine Papiernik is a Noema Pharma board member and Chairman and Managing Partner of Sofinnova Partners. He joined Sofinnova in1997 and has backed life-sciences companies through its Capital Funds. Sofinnova founded and seed-financed Noema; the firm’s investment is distinct from any personal check by Papiernik.

David Evans is now a Partner in Sofinnova’s Crossover Strategy, which he joined in June2026. Sofinnova’s own biography and July13,2026 appointment release confirm he previously served as Roche Venture Fund investment director, latterly senior investment director. Earlier Roche work included global data science for neuroscience and rare diseases. His existing Sofinnova role is preserved. Exact Roche departure day is unknown.

Biotechnology company builder, partner in Sofinnova’s Biovelocita strategy and CEO of BioClec, which develops microglia-targeted therapies for Alzheimer’s disease.

PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Jiaping Gu, PhD, is a Partner at Pfizer Ventures and Vice President, Worldwide Business Development. Jiaping is responsible for identifying, evaluating, making and managing equity investments aligned with the future scientific and strategic directions of Pfizer. He manages Pfizer’s venture investments in early-stage biotechnology companies, with a particular focus on opportunities in China. Jiaping brings 10+ years of investment experiences in both public and private life science companies. Prior to Pfizer Ventures, Jiaping is a Partner at Takeda Ventures, where he was responsible for sourcing and executing investments aligned with Takeda’s R&D strategy and managing Takeda’s equity portfolio. Prior to Takeda Ventures, Jiaping was Vice President at Hillhouse Investment, where he was a member of the Bioventure team covering private stage biotech investments in the US and Europe. Previously he has more than 10 years of research experiences focusing on neurodegeneration in the pharmaceutical industry and academic institutions. Jiaping earned his PhD in Neuroscience from Rutgers University and received his BS in Biological Sciences from Tsinghua University in China.

Richard J. Thompson is Professor of Molecular Hepatology at King’s College London and a paediatric liver disease specialist. He researches the genetic basis of liver disorders and advises Integra Therapeutics on clinical applications. The middle initial is established by his university publication record.

General partner at Backstage Capital with prior investment experience at #ANGELS, Village Capital and Techstars, and banking and startup operating experience.

Founder of Backstage Capital, investing in technology companies led by underrepresented founders; announced a transition to a chair and advisory role after leading the firm.

Novoron Bioscience COO, co-founder and director, with experience in financial planning, startup funding and business development.

Novoron Bioscience CEO, co-founder and board chairman; UC San Diego-trained biomedical scientist researching LDL receptor biology in neurological injury and disease.

Robert Eastlack serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.

Bryn Martin serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.

Linda Jones serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.

Michael G. Fehlings serves Novoron Bioscience as Spinal Cord Injury Advisory Council Member.

Miguel de los Rios serves Novoron Bioscience as Scientific Advisory Board Member.

Rivka Kreitman serves Novoron Bioscience as Scientific Advisory Board Member.

James Whisstock serves Novoron Bioscience as Scientific Advisory Board Member.

Jeff Goldberg serves Novoron Bioscience as Scientific Advisory Board Member.

Kurt Brunden serves Novoron Bioscience as Scientific Advisory Board Member.

Jennifer Rauch serves Novoron Bioscience as Scientific Advisory Board Member.

Lawrence Goldstein serves Novoron Bioscience as Scientific Advisory Board Member.

Novoron Bioscience CFO supporting financial strategy and business development; life sciences finance adviser with mechanical engineering and business administration training.

Novoron Bioscience specialist in nonclinical translation and business development; neuroscientist with prior regenerative medicine and nonclinical development leadership experience at Athersys.

Drug discovery and development specialist at Novoron Bioscience; medicinal chemist with prior chemistry leadership experience at Artizan Biosciences and Viamet Pharmaceuticals.

Novoron Bioscience is a San Diego biotechnology company developing therapies for neurodegenerative disease and spinal cord injury using low-density lipoprotein receptor biology. Founded in 2014 by Travis Stiles and Shawn Gahr, it targets disease-related LRP1 signaling and protein interactions while seeking to preserve normal receptor functions. Its programs address tau and other protein propagation, neuronal repair and recovery after spinal cord injury. Novoron also develops human brain organoid screening tools, combining transcriptomic and AI-supported analyses to evaluate Alzheimer's disease drug candidates. Its leadership includes CEO and co-founder Travis Stiles, executive chairman David Weiner, COO and co-founder Shawn Gahr, drug discovery and translation specialists, and financial leadership. The company is supported by scientific and spinal cord injury advisory groups. Two Bear Capital led seed financings in 2021 and 2022. Its therapies remain investigational, and its Australian subsidiary Novoroo is pursuing preclinical NOVO-120 research for bladder dysfunction after spinal cord injury.

Barcelona-based biotechnology company developing next-generation targeted therapeutics at the preclinical stage. Created with the backing of Invivo Partners, the company is currently operating in stealth and has not publicly disclosed its molecular targets, technology platform, disease indications or development candidates. Nicole Clarke leads the company as chief executive, and Invivo partner Laura Rodríguez Gallego chairs its board.

SV Health Investors investor relations director supporting fundraising for its biotechnology and dementia strategies; previously worked in private equity fundraising.

Dementia Discovery Fund scientific adviser and drug discovery executive; joined GSK in 2025 after scientific leadership roles at BenevolentAI and Pfizer.

SV Health Investors UK chief financial officer and partner, supporting European fund finance operations including the Dementia Discovery Funds.

Dementia Discovery Fund scientific adviser with translational drug research experience at Astex, SuperGen and Onyx Pharmaceuticals.

Dementia Discovery Fund scientific adviser with research strategy experience at Alzheimer's Research UK and the MS Society, and cancer biology and immunology training.

Dementia Discovery Fund scientific adviser and neuroscience research executive; joined Biogen in 2025 after research leadership roles at NeuroSolutions, Lundbeck and Servier.

Dementia Discovery Fund scientific adviser and neuroscientist with neurodegeneration research and development experience at Janssen, Novartis and Merck.

Dementia Discovery Fund scientific adviser with pharmaceutical neuroscience and molecular imaging leadership experience, including Bristol Myers Squibb, Biogen and Merck.

Dementia Discovery Fund scientific adviser and pharmacologist with academic and pharmaceutical leadership experience in central nervous system drug discovery.

Dementia Discovery Fund scientific adviser and neuroscientist with experience leading Alzheimer's Association research initiatives and international dementia science programs.

Dementia Discovery Fund scientific adviser and pharmacologist with research and drug development experience in neurodegeneration, pain and migraine at Eli Lilly.

Dementia Discovery Fund scientific adviser with biochemistry training and experience directing health and life sciences initiatives at Gates Ventures. Niranjan Bose is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Managing Director, Health and Life Sciences, Gates Ventures, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment. The ADDF biography identifies him as GatesVentures managing director for Health and LifeSciences and science adviser to BillGates, following service at the GatesFoundation; these are distinct institutions. Niranjan Bose is managing director of Health & Life Sciences Strategy at Gates Ventures LLC and scientific adviser to Bill Gates, as confirmed by the March 2026 ADDF Alzheimer’s Insights Summit biography. He joined the office in August 2014 after working at the Gates Foundation between 2007 and 2014. He also serves as interim executive director of the Alzheimer’s Disease Data Initiative.

Dementia Discovery Fund scientific adviser and neuroscientist with pharmaceutical clinical development and venture investment experience, including Pfizer Ventures. PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Rana Al-Hallaq, PhD is Partner and Head of Operations at Pfizer Ventures and Vice President, Worldwide Business Development. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in Autifony Therapeutics, Biograph55, Enara Bio, Montis Biosciences, Nucleome Therapeutics, ReCode Therapeutics, RefleXion Medical, TwoStep Therapeutics, and Vivet Therapeutics. Her prior investment responsibilities include Cortexyme, Jnana Therapeutics, Mitokinin, Triplet Therapeutics, and VectivBio. She is also responsible for managing investments in the Dementia Discovery Funds, the Health Enterprise Partners Fund, and the Wellington Venture Investments Fund. Rana serves as Vice Chair on the New York BIO Board of Directors. Prior to her current role, Rana was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health. Rana graduated Summa Cum Laude and Phi Beta Kappa with a BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.

Executive assistant on the Dementia Discovery Fund team since 2023, with prior financial services operations experience at BNY Mellon.

Dementia Discovery Fund venture partner and Endlyz co-founder and CEO; biochemist with prior Lilly neurodegeneration drug discovery experience.

Executive assistant supporting Dementia Discovery Fund's London partners; previously supported LifeArc leadership and worked in healthcare investor relations.

Dementia Discovery Fund venture partner and neurologist with neuroscience clinical development experience; formerly chief medical officer at Alector and Passage Bio.

Dementia Discovery Fund venture partner with neuroscience drug discovery experience; formerly chief scientific officer at Alzheimer's Research UK and a Pfizer research leader.

Dementia Discovery Fund venture partner specializing in neurological clinical development; previously led neurology medical strategy at IQVIA. Lynne Hughes is a scientific adviser to NeuroVision Imaging’s BrainHealth programme. Former VP and Global Head, Medical Strategy, Neurology at IQVIA, Dr. Hughes is currently a member of the NIA-NIH task force for recruitment into Alzheimer’s trials and of the G7 & G20 World Dementia Councils. She is also co-chair of the DAVOS (DAC) taskforce for expediting clinical Alzheimer’s trials.

Dementia Discovery Fund venture partner and neurologist with academic and pharmaceutical research experience in protein aggregation and neurodegenerative disease. Damian Crowther is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: Having trained in clinical neurology in Oxford, Nottingham and Cambridge, Damian then lead a neuroscience research group at the Cambridge Institute for Medical Research and Department of Genetics, University of Cambridge. Damian moved to industry in 2015, becoming the Director and Head of Early R&D with AstraZeneca Neuroscience.  He is Entrepreneur in Residence at Cambridge Innovation Capital and Venture Partner at SV’s Dementia Discovery Fund. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check. Damian Crowther co-founded TRIMTECH and leads research. A neurologist and neuroscience entrepreneur, he previously led early discovery at AstraZeneca Neuroscience and conducted academic research at Cambridge. His entrepreneur-in-residence work includes DDF, CIC and Oxford Science Enterprises; he also co-founded GPnotebook. Damian Crowther is listed by Cambridge Innovation Capital as entrepreneur in residence. Life-sciences entrepreneur in residence with clinical neurobiology and early neuroscience drug-discovery experience, including AstraZeneca; existing TRIMTECH and other affiliations remain preserved. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets.

Dementia Discovery Fund associate with Cambridge research experience in inflammation and Parkinson's disease; promoted from senior analyst in 2025.

Gradiant in Residence supporting Dementia Discovery Fund investment work and partnerships; also a strategic planning executive at Gradiant in South Korea.

Dementia Discovery Fund associate and neuroscientist; previously a Bloomberg Intelligence analyst covering neurodegeneration, neuropsychiatry and rare disease companies.

Dementia Discovery Fund vice president and neuroscientist with experience in Alzheimer's disease research and pharmaceutical strategy consulting.

Biotechnology company developing treatments for rare genetic diseases of the central nervous system. Its lead product, leriglitazone, is a brain-penetrant selective PPAR-gamma agonist developed for X-linked adrenoleukodystrophy, with additional clinical programs in Rett syndrome and Friedreich’s ataxia. In September 2026 the European Commission authorised NEZGLYAL (leriglitazone) under exceptional circumstances for a defined group of boys aged 2–12 with cerebral adrenoleukodystrophy and non-enhancing brain lesions; other indications remain in development. Minoryx conducts drug discovery, translational research and clinical development from Mataró, Spain, and Gosselies, Belgium, and works with Neuraxpharm on European commercialisation and continued development.

Director of Translational Sciences at Minoryx, with a PhD in Human Molecular Genetics from the University of Barcelona and research experience in rare neurological and mitochondrial diseases. Her full surname appears as Laura Rodriguez-Pascau in the Minoryx-affiliated author list of the NEXUS interim analysis. She is distinct from Invivo Partners investor Laura Rodríguez.

Biotechnology contract development and manufacturing company in Zamudio, Bizkaia, producing synthetic DNA starting materials for genetic medicines. Its proprietary cell-free enzymatic platform makes optimised linear DNA and pure synthetic oDNA for mRNA vaccines and therapeutics, cell therapies, gene editing, and viral and non-viral gene therapies. It supplies biotechnology customers with customised DNA, process development and GMP manufacturing services, reducing reliance on bacterial plasmid fermentation. Founded in 2021 by Columbus Venture Partners, Syngoi was acquired by Artis BioSolutions in 2026 and operates under the unified Artis brand from July 2026. Its Spanish operations form part of Artis’s integrated synthetic DNA and advanced-therapy manufacturing platform.

Adviser to Two Bear Capital and Chief Customer Experience Officer at Pure Storage; previously a Cisco services executive.

Adviser to Two Bear Capital; MD Anderson oncologist and immunologist studying cancer immunotherapy and resistance to immune checkpoint treatment.

Senior Biopharmaceutical Adviser to Two Bear Capital; formerly Executive Director of Biologics Discovery at Amgen.

Adviser to Two Bear Capital and CEO of Evolve Biologics; previously CEO of Dendreon Pharmaceuticals.

Adviser to Two Bear Capital; MD Anderson immunologist and Nobel laureate whose research contributed to cancer immune checkpoint therapies.

Head of Community Engagement at Two Bear Capital; previously founded and led Montana's Frontier Angels investor network.

Executive Assistant supporting Two Bear Capital's Menlo Park team, with previous work in investment and asset management.

Executive Assistant supporting Two Bear Capital operating partners, with prior executive support experience in technology and pharmaceuticals.

Head of Research at Two Bear Capital; UC San Diego-trained neuroscientist with experience in therapeutic development and medical affairs.

Partner and Head of Capital Formation at Two Bear Capital; previously led capital formation at SOSV and worked with institutional investors at BlackRock and other firms.

Partner and Head of Operations at Two Bear Capital, focused on financial management and portfolio services; previously worked at Sequoia Capital.

Operations Manager at Two Bear Capital responsible for internal processes, budgets and day-to-day operations.

Executive Assistant to Two Bear Capital founder Mike Goguen, with experience supporting executive operations at startups.

Chief Information Officer at Two Bear Capital, leading AI, data and analytics strategy; previously held solutions engineering leadership roles at StarTree and Cockroach Labs.

Operating Partner for enterprise companies at Two Bear Capital; former revenue leader at StarTree and Cockroach Labs.

Operating Associate at Two Bear Capital supporting life sciences portfolio companies and AI implementation; former healthcare consultant and biotechnology business development professional.

Head of Strategic Talent at Two Bear Capital with experience recruiting and developing teams in technology, healthcare and professional services.

Venture Partner at Two Bear Capital; former Leerink Partners research director and healthcare investment strategist.

Partner and Head of Platform at Two Bear Capital, leading portfolio support and founder programs; Babson College business communication professor and executive coach.

Partner at Two Bear Capital with healthcare investment banking experience and prior advisory work for Emerson Collective's health investing team.

Principal at Two Bear Capital investing in drug discovery platforms; Harvard-trained scientist with single-cell genomics and biotechnology strategy experience.

Partner at Two Bear Capital focused on therapeutics, diagnostics, tools and medical devices, including oncology and neurodegeneration.

Partner at Two Bear Capital; cybersecurity specialist, former Google Chrome security team leader and co-founder of Divergent Security.

Principal at Two Bear Capital focused on therapeutics; MIT-trained neuroscientist with research experience in Alzheimer's disease models and tissue imaging.

Associate at Two Bear Capital focused on AI, quantum computing and cybersecurity, with applied mathematics and data analysis experience.

Partner at Two Bear Capital investing in life sciences, AI and cybersecurity; formerly COO and CTO of Adaptive Biotechnologies.

Founder and Managing Partner of Two Bear Capital; previously a Sequoia Capital investor with engineering experience in technology and life sciences.

Associate at RTK Group; holds a PhD according to the firm's current public team page.

Senior Associate in Operations at RTK Group.

Senior Associate in Finance at RTK Group.

RTK Group is a family office backed biopharmaceutical advisory and investment firm founded by Teena Kohli in December 2019. It supports biotechnology, pharmaceutical, medical device and diagnostics businesses with capital and hands-on help in company formation, technology development and commercialization. The firm invests across private and public company development stages. Its publicly listed team includes Founding Partner Teena Kohli, Managing Director Neal Muni, finance and operations associates, and a scientific associate. RTK participated in Unravel Biosciences' seed financing announced in June 2022, supporting its AI-enabled drug discovery and patient stratification platform for complex neurological diseases. Other companies on its portfolio page include BridgeHealth Pharmaceuticals and Romeg Therapeutics.

Founding Partner of RTK Group, which she founded in December 2019; physician and Tufts University infectious disease specialist with clinical research and biotechnology advisory experience.

Computational biologist and adviser to Unravel Biosciences; Harvard and Dana-Farber researcher working on gene regulatory networks and health data.

Psychiatrist and adviser to Unravel Biosciences; Massachusetts General Hospital researcher focused on bipolar disorder, depression and clinical trials.

Neuroscientist and adviser to Unravel Biosciences, with prior research leadership roles at Harvard and UC Santa Barbara.

Adviser to Unravel Biosciences and co-founder and CEO of Aptabridge Therapeutics, with experience leading biotechnology operations and drug development.

Co-founder and adviser to Unravel Biosciences; Tufts University biologist studying developmental biology, regeneration and bioelectric signaling.

Co-founder and adviser to Unravel Biosciences; Donald E. Ingber is founding director of Harvard's Wyss Institute and a researcher in mechanobiology and Organ Chip technology.

Program Manager at Unravel Biosciences coordinating therapeutic development projects and partnerships across its rareSHIFT portfolio.

Business Development Manager at Unravel Biosciences supporting Predictable Medicine and rareSHIFT partnerships with industry, patient foundations and healthcare institutions.

Senior Computational Biologist at Unravel Biosciences, focusing on explainable computational models and biological network analysis.

Data Scientist at Unravel Biosciences working on data processing, visualization and reporting; previously an intensive care nurse.

Research Associate at Unravel Biosciences, working on tadpole drug screens and clinical study coordination for rareSHIFT.

Lead Computational Scientist at Unravel Biosciences; computer scientist developing the company's computational architecture, with prior Dell/EMC engineering experience.

Therapeutic Portfolio Director at Unravel Biosciences, coordinating computational and experimental drug discovery; previously developed Xenopus screening methods at the Wyss Institute.

Computer Engineer at Unravel Biosciences, working on computational drug screening and patient stratification, with prior healthcare software experience at Intermountain Healthcare.

Chief Medical Officer of Unravel Biosciences and Managing Director of RTK Group; physician and former Azurity Pharmaceuticals CEO with industry, FDA and healthcare investment banking experience.

Co-founder and Chief Scientific Officer of Unravel Biosciences; molecular biologist with prior Wyss Institute and SRI International research experience.

Co-founder and CEO of Unravel Biosciences; bioengineer and former Wyss Institute lead engineer working on drug discovery, disease models and laboratory automation.

Unravel Biosciences is a Boston clinical-stage biotechnology company founded in 2021 from Harvard's Wyss Institute. It uses AI systems biology and patient RNA data to discover drug targets, identify potential treatments and stratify patients with rare and complex diseases. Its BioNAV platform models biological networks and combines computational predictions with experimental screening, including its automated SquishyWare tadpole disease models. The company's Predictable Medicine approach and Living Molecular Twins support drug development, while its rareSHIFT program makes the platform available to patient foundations and biotechnology partners. Its investigational RVL-001 program, a proprietary formulation of vorinostat, entered proof-of-concept studies for Rett syndrome and Pitt Hopkins syndrome in Colombia, with first patient dosing announced in May 2026. Additional programs explore neurological and metabolic diseases. Richard Novak and Frederic Vigneault lead the company as co-founders and CEO and CSO, alongside Chief Medical Officer Neal Muni. RTK Group disclosed participation in seed financing in June 2022, and KdT Ventures lists Unravel in its portfolio.

Spanish private capital investment group, formerly GED Capital, investing through buyout, venture capital, healthcare and infrastructure strategies in Spain, Portugal and other European markets. It supports companies through acquisitions, operational development, international expansion and digitalisation, including adoption of AI. Its healthcare growth strategy, developed with Columbus Venture Partners, backs medicines, diagnostics, precision medicine, medical equipment, health software and scientific manufacturing services approaching or already in commercial operation. The group operates through regulated management companies including Buenavista Buyout, the registered manager of its healthcare and third buyout funds.

PLD Space board director and CDTI technology-company capitalization specialist. Quibim’s own public board directory identifies the native same-name person as Head of Capitalization of Technology Companies at CDTI; PLD Space’s own published event post independently identifies him with CDTI. Board affiliation is distinct from employment.

Apollo Health Ventures current own career biography: Jeanne is a member of the Advisory Board at apollo.vc With over 35 years of expertise in the pharmaceutical industry, Jeanne has held various managerial positions encompassing research and development, commercial operations, business development, and venture investment. During the last decade, Jeanne served as the Vice President of venture investment within Johnson & Johnson's corporate venture fund, Johnson & Johnson Innovation - JJDC. Before her tenure at JJDC, she worked as a director in the business development team at GlaxoSmithKline. Outside appointments are source-published career context; a manager/issuer board role is not a personal financing check.